1,154 results on '"Patterson, A."'
Search Results
2. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells
3. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects
4. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
5. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma
6. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism
7. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
8. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
9. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia
10. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
11. Lysyl oxidase is associated with increased thrombosis and platelet reactivity
12. Histones to the cytosol: exportin 7 is essential for normal terminal erythroid nuclear maturation
13. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
14. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia
15. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
16. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
17. The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia
18. Management and Outcomes of Venous Thromboembolism in Adults with Immune Thrombocytopenia
19. Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia
20. Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
21. Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
22. Arterial Thromboembolism Is Prevalent and Often Suboptimally Managed in Immune Thrombocytopenia
23. Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
24. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia
25. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
26. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
27. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
28. Arterial Thromboembolism Is Prevalent and Often Suboptimally Managed in Immune Thrombocytopenia
29. Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
30. Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
31. Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia
32. Management and Outcomes of Venous Thromboembolism in Adults with Immune Thrombocytopenia
33. Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
34. BMP activity controlled by BMPER regulates the proinflammatory phenotype of endothelium
35. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab
36. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
37. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia
38. The ERK1/2 Regulator WNK2 Shows Differential Expression and Isoform Usage, Primarily Driven By Aberrant Methylation, in MYD88 Mutated Waldenström's Macroglobulinemia
39. A New Role for the SRC Family Member HCK As a Driver of BCR/SYK Signaling in MYD88 Mutated Lymphomas
40. Bob.1 Blocks a SYK Protein Degradation Pathway in Mice That Develop Chronic Graft Versus Host Disease Manifestations
41. Nitric Oxide Dependent Metabolism Regulates the Proliferation and Differentiation of Stress Erythroid Progenitors
42. Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations
43. NFATC2 regulates Targets of MYC Signaling in MLL-AF9 AML
44. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
45. CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia
46. Thalidomide and rituximab in Waldenstrom macroglobulinemia
47. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
48. Establishment of the Bcwm.2 Cell Line As a BTK-Inhibitor Resistant, BCL2 Inhibitor Sensitive in Vitro and In Vivo Study Model for Waldenström's Macroglobulinemia
49. Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
50. Liver Sinusoidal Endothelial Cells but Not Hepatocytes Express a Fluorescent Reporter Under the Endogenous F8 Promoter in a New Hemophilia a Mouse Model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.